tracken
Revance Therapeutics, Inc. Aktie News
Positiv
InvestorPlace
●
3 Tage alt
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company.
Positiv
InvestorPlace
●
14 Tage alt
Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.
Neutral
Seeking Alpha
●
16 Tage alt
Revance Therapeutics Inc. (NASDAQ:RVNC ) Q1 2024 Results Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Laurence Watts - Investor Relations, New Street IR Mark Foley - Chief Executive Officer Tobin Schilke - Chief Financial Officer Conference Call Participants Seamus Fernandez - Guggenheim Partners Stacy Ku - TD Cowen Annabel Samimy - Stifel Financial Chris Shibutani - Gol...
Neutral
Business Wire
●
17 Tage alt
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update.
Neutral
Business Wire
●
17 Tage alt
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia.
Neutral
Business Wire
●
24 Tage alt
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024.
Neutral
Business Wire
●
etwa ein Monat alt
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.
Neutral
Business Wire
●
etwa 2 Monate alt
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
